Search
Search Results
-
(Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at iliac crest and tumor load shown by MRI
In multiple myeloma and its precursor stages, precise quantification of tumor load is of high importance for diagnosis, risk assessment, and therapy...
-
Vitamin D receptor gene polymorphisms and multiple myeloma: a meta-analysis
Vitamin D acts through the vitamin D receptor (VDR), and vitamin D level decreases in multiple myeloma (MM) patients. Single nucleotide polymorphisms...
-
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
BackgroundIsatuximab, an anti-CD38 antibody, has been widely used in treatments for patients with relapsed/refractory multiple myeloma (MM). Despite...
-
Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma
BackgroundAlthough most studies on the cardiovascular toxicity of proteasome inhibitors have focused on carfilzomib, the risk of cardiotoxicity...
-
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
Multiple myeloma (MM) remains a challenging hematologic malignancy despite advancements in chimeric antigen receptor T-cell (CAR-T) therapy. Current...
-
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients....
-
Bispecific Antibodies for the Treatment of Multiple Myeloma
Purpose of ReviewAdvances in multiple myeloma therapies have greatly improved outcomes for patients living with the disease, although to date there...
-
Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain
BackgroundGain and amplification of 1q21 (1q21+) are adverse chromosomal aberrations of multiple myeloma (MM) that lead to refractoriness to a...
-
Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis
BackgroundImpaired immune response in multiple myeloma renders the patients vulnerable to infections, such as COVID-19, and may cause worse response...
-
Progress of modern imaging modalities in multiple myeloma
Multiple myeloma (MM) is an incurable hematological malignancy, but treatment advances made in the last two decades have markedly improved its...
-
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
BackgroundRuxolitinib (RUX), an orally administered selective Janus kinase 1/2 inhibitor, has received approval for the treatment of myelofibrosis,...
-
Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
The introduction of daratumumab has improved treatment outcomes for multiple myeloma (MM). However, infectious complications are a concern in...
-
Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study
ObjectivePoor adherence to oral chemotherapy adversely impacts clinical outcomes and escalates overall healthcare costs. Despite barriers to...
-
Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy
Transcripts longer than 200 nucleotides that are not translated into proteins are known as long non-coding RNAs, or lncRNAs. Now, they are becoming...
-
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan
This post-marketing surveillance assessed the safety and effectiveness of isatuximab plus pomalidomide and dexamethasone (Isa-Pd) for relapsed or...
-
High patient satisfaction and increased physical activity following a remote multidisciplinary team multiple myeloma clinic
PurposePatients with multiple myeloma suffer from disease-related complications such as bone destruction, toxicities from repeated therapies and...
-
The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states
PurposeMultiple myeloma is a largely incurable disease. Patients suffer from the cancer, therapeutic side effects, and often psychological symptoms....
-
Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis
Post-transplantation therapy is commonly performed in patients with myeloma and can prolong progression-free survival (PFS). However, whether...
-
KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway
PurposeMultiple myeloma (MM) is an incurable hematological malignancy characterized by clonal proliferation of malignant plasma B cells in bone...
